Enhertu-Induced Resistant Tumor Models
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies. However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models. WuXi AppTec offers validated, Enhertu-induced resistant tumor models to support project teams focused on ADC therapeutics against breast and lung cancer.
Learn about our comprehensive platform of ADC services by clicking HERE
Enhertu-induced resistant tumor models
Related Content
WuXi AppTec provides integrated and cost-effective services for: Polyclonal and monoclonal antibodies Anti-drug antibodies (ADA), host cell protein (HCP) antibodies,...
VIEW RESOURCEAntibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
VIEW RESOURCE